TFDA Approves SteriPlas in Taiwan
It is with great pleasure that we announce the SteriPlas Cold Plasma medical device is now an approved product in Taiwan, making it the first Cold Plasma medical device to be issued in the country. Adtec Healthcare Limited owes its thanks and praises to our exclusive distributor in Taiwan, SG Biomedical, whom without their skills in Regulatory and with the TFDA, none of this would have been possible.
The SteriPlas is already renowned in Taiwan for its strong clinical efficacy using premium and dense Cold Plasma and is set for distribution across the leading hospitals dealing with wound care. This is set to start within the coming months. If you are a health care professional in Taiwan that manages chronic wounds, we humbly request that you contact SG Biomedical who can guide you on the strong antibacterial benefits of the SteriPlas for diabetic foot ulcers, LVAD infections, sternal wounds and many more.
http://www.sghlds.com/index.php/tw/
SteriPlas Cold Plasma to be presented at EACTS 2023
We look forward to Mr Thomas Schlöglhofer’s presentation at the upcoming European Association for Cardio-Thoracic Surgery (EACTS) conference in Vienna on Fri 6th Oct. Thomas will present, “Cold Atmospheric Plasma Therapy as an Effective Treatment of Left Ventricular Assist Device Driveline Infections” which will feature the advantages of our SteriPlas Cold Plasma medical device for deep LVAD infections treated at the Department of Cardiac Surgery, Medical University of Vienna.
Adtec presents at the LSI today
It was a pleasure to present at the LSI - Life Science Intelligence in Barcelona today. The successes of Adtec Healthcare Ltd and our Premium Cold Plasma medical device, the SteriPlas, were presented to the audience with much interest.
If you would like to know more about our strong clinical efficacy and antibiofilm properties for chronic wounds and infections, send us an email at info@adtecplasma.com
First day at the LSI
An epic start to the first day at LSI - Life Science Intelligence in Barcelona.
It has been a pleasure to interact with professionals sharing the same interest in tackling strains on the global wound care market. The benefits that the clinically proven SteriPlas can bring to significantly reduce bed occupancy, chronic infections and the financial burden rates have been demonstrated.
We look forward to presenting more about this on the 21st Sept and encourage you to meet with us whilst at LSI to learn more about our Premium Cold Plasma medical device for chronic wounds, surgical site infections and medical dermatology conditions.
Day 1 of the EUMS
We're having a great time at the #EUMS2023 conference catching up with friends and connecting with new faces interested in our Cold Plasma for LVAD infection management.
We encourage you to visit us whilst you're here to see our Premium Cold Plasma medical device, the SteriPlas, renowned for its antibiofilm properties.